[
  {
    "ts": null,
    "headline": "Inside Pfizer’s Drug-Pricing Deal With the Trump Administration",
    "summary": "Inside Pfizer’s Drug-Pricing Deal With the Trump Administration",
    "url": "https://finnhub.io/api/news?id=98043648fbda120294f967610633ff6baf2afc16de06120be80a350994bf00fd",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759441560,
      "headline": "Inside Pfizer’s Drug-Pricing Deal With the Trump Administration",
      "id": 137016821,
      "image": "",
      "related": "PFE",
      "source": "DowJones",
      "summary": "Inside Pfizer’s Drug-Pricing Deal With the Trump Administration",
      "url": "https://finnhub.io/api/news?id=98043648fbda120294f967610633ff6baf2afc16de06120be80a350994bf00fd"
    }
  },
  {
    "ts": null,
    "headline": "Centene, QuidelOrtho, iRhythm, and Bio-Techne Shares Skyrocket, What You Need To Know",
    "summary": "A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations.",
    "url": "https://finnhub.io/api/news?id=fdc898911eaa47fc69ce2e4905bc3d6558c4e347ad96247869e9764a01cb4818",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759434650,
      "headline": "Centene, QuidelOrtho, iRhythm, and Bio-Techne Shares Skyrocket, What You Need To Know",
      "id": 136959912,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations.",
      "url": "https://finnhub.io/api/news?id=fdc898911eaa47fc69ce2e4905bc3d6558c4e347ad96247869e9764a01cb4818"
    }
  },
  {
    "ts": null,
    "headline": "agilon health, Tandem Diabetes, NeoGenomics, Hims & Hers Health, and Oscar Health Stocks Trade Up, What You Need To Know",
    "summary": "A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations.",
    "url": "https://finnhub.io/api/news?id=84c09a7b6806ce9ccb22a9fee3d22cd6b1be219c178c1e057faf5cf7625bb63b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759434649,
      "headline": "agilon health, Tandem Diabetes, NeoGenomics, Hims & Hers Health, and Oscar Health Stocks Trade Up, What You Need To Know",
      "id": 136959913,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations.",
      "url": "https://finnhub.io/api/news?id=84c09a7b6806ce9ccb22a9fee3d22cd6b1be219c178c1e057faf5cf7625bb63b"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Down, Paring Gains From Pfizer Deal -- Health Care Roundup",
    "summary": "Health Care Down, Paring Gains From Pfizer Deal -- Health Care Roundup",
    "url": "https://finnhub.io/api/news?id=5c1ebdc77d86c9192e60ac6687097c29372814cae05e4ef4da91741e7e6ccd51",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759426260,
      "headline": "Health Care Down, Paring Gains From Pfizer Deal -- Health Care Roundup",
      "id": 137110318,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Health Care Down, Paring Gains From Pfizer Deal -- Health Care Roundup",
      "url": "https://finnhub.io/api/news?id=5c1ebdc77d86c9192e60ac6687097c29372814cae05e4ef4da91741e7e6ccd51"
    }
  },
  {
    "ts": null,
    "headline": "Buy Novo Nordisk Stock as Health Names Return to Favor, Analyst Says",
    "summary": "HSBC made the call as it listed the pharma stocks it sees as best positioned to play a recovery in the sector.",
    "url": "https://finnhub.io/api/news?id=71f2be6d42a57c4dd8e4ded6c5201d00a607f13283c5cf8076e9af35ae5b3c5c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759423920,
      "headline": "Buy Novo Nordisk Stock as Health Names Return to Favor, Analyst Says",
      "id": 136959914,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "HSBC made the call as it listed the pharma stocks it sees as best positioned to play a recovery in the sector.",
      "url": "https://finnhub.io/api/news?id=71f2be6d42a57c4dd8e4ded6c5201d00a607f13283c5cf8076e9af35ae5b3c5c"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca Stock Is Up 10% on Tariff News. But Is the Pharmaceutical Giant a Buy?",
    "summary": "The uncertainty about U.S. pharmaceutical tariffs shouldn't be as worrisome for AstraZeneca now.",
    "url": "https://finnhub.io/api/news?id=4d71280f92d3a9cd78e0a2ecefcf5c8155ae03c5bd980b22d278b66f7adaeab4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759422166,
      "headline": "AstraZeneca Stock Is Up 10% on Tariff News. But Is the Pharmaceutical Giant a Buy?",
      "id": 136960226,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The uncertainty about U.S. pharmaceutical tariffs shouldn't be as worrisome for AstraZeneca now.",
      "url": "https://finnhub.io/api/news?id=4d71280f92d3a9cd78e0a2ecefcf5c8155ae03c5bd980b22d278b66f7adaeab4"
    }
  },
  {
    "ts": null,
    "headline": "Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency?",
    "summary": "Moderna plans up to 10 product launches over four years, aiming to cut reliance on fading COVID-19 vaccine sales.",
    "url": "https://finnhub.io/api/news?id=8d687c97057e476f96c06879559a7b7f894130bb1ceea45fbd112b66696ef077",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759415520,
      "headline": "Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency?",
      "id": 136960113,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Moderna plans up to 10 product launches over four years, aiming to cut reliance on fading COVID-19 vaccine sales.",
      "url": "https://finnhub.io/api/news?id=8d687c97057e476f96c06879559a7b7f894130bb1ceea45fbd112b66696ef077"
    }
  },
  {
    "ts": null,
    "headline": "Market Chatter: White House Asking Companies to Make Deals Ahead of Midterm Elections",
    "summary": "The White House is asking pharmaceutical and other companies for deals meant to boost the popularity",
    "url": "https://finnhub.io/api/news?id=0c09b61ff324ec415d02050cac9142a892427322cfacc6af1323f139ae85e712",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759405900,
      "headline": "Market Chatter: White House Asking Companies to Make Deals Ahead of Midterm Elections",
      "id": 136955299,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The White House is asking pharmaceutical and other companies for deals meant to boost the popularity",
      "url": "https://finnhub.io/api/news?id=0c09b61ff324ec415d02050cac9142a892427322cfacc6af1323f139ae85e712"
    }
  },
  {
    "ts": null,
    "headline": "3 Things You Need to Know if You Buy Pfizer Today",
    "summary": "Pfizer has an attractive 7.2% dividend yield, but there are some pros and cons you need to understand before you buy it.",
    "url": "https://finnhub.io/api/news?id=f5ef40876fbf4a0fecef690c909cdb4b6fff961ea50d7c7ab73223322d226fb6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759402920,
      "headline": "3 Things You Need to Know if You Buy Pfizer Today",
      "id": 136955462,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer has an attractive 7.2% dividend yield, but there are some pros and cons you need to understand before you buy it.",
      "url": "https://finnhub.io/api/news?id=f5ef40876fbf4a0fecef690c909cdb4b6fff961ea50d7c7ab73223322d226fb6"
    }
  },
  {
    "ts": null,
    "headline": "Why Pfizer’s Trump Deal Is Good News for All of Big Pharma",
    "summary": "Big Pharma has been out of favor with investors on fears of tariffs and price controls.  On Tuesday,  Pfizer  Chief Executive  Albert Bourla  stood alongside President  Trump  at the White House to unveil “TrumpRx,” a government website that will allow Americans to buy certain medicines at discounted cash prices.  According to Pfizer, the price cuts on its products will average around 50% and in some cases reach as high as 85%.",
    "url": "https://finnhub.io/api/news?id=76fb81f6886799a743f312b7892d79d50f67825558630be2199b44be018325d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759402800,
      "headline": "Why Pfizer’s Trump Deal Is Good News for All of Big Pharma",
      "id": 136955463,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Big Pharma has been out of favor with investors on fears of tariffs and price controls.  On Tuesday,  Pfizer  Chief Executive  Albert Bourla  stood alongside President  Trump  at the White House to unveil “TrumpRx,” a government website that will allow Americans to buy certain medicines at discounted cash prices.  According to Pfizer, the price cuts on its products will average around 50% and in some cases reach as high as 85%.",
      "url": "https://finnhub.io/api/news?id=76fb81f6886799a743f312b7892d79d50f67825558630be2199b44be018325d4"
    }
  },
  {
    "ts": null,
    "headline": "3 Mega Dividend Stocks With Yields as High as 13.4%",
    "summary": "These dividend stocks offer the potential to produce big-time income streams.",
    "url": "https://finnhub.io/api/news?id=af9130cce898cb76d5409056f7011e68053f3fd8456ebe166f3c73737d55eed3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759396260,
      "headline": "3 Mega Dividend Stocks With Yields as High as 13.4%",
      "id": 136955465,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "These dividend stocks offer the potential to produce big-time income streams.",
      "url": "https://finnhub.io/api/news?id=af9130cce898cb76d5409056f7011e68053f3fd8456ebe166f3c73737d55eed3"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: The Long Suffering Is Finally Over (Rating Upgrade)",
    "summary": "Pfizer Inc. has secured an MFN pricing deal with the White House, easing recent tariff and drug repricing concerns while affording a win for Trump. Learn more about PFE stock here.",
    "url": "https://finnhub.io/api/news?id=81003a9a812cd79f48f311793fe9c834dcc9816d53a49ec1bd27bef30d8c934e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759395600,
      "headline": "Pfizer: The Long Suffering Is Finally Over (Rating Upgrade)",
      "id": 136955114,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. has secured an MFN pricing deal with the White House, easing recent tariff and drug repricing concerns while affording a win for Trump. Learn more about PFE stock here.",
      "url": "https://finnhub.io/api/news?id=81003a9a812cd79f48f311793fe9c834dcc9816d53a49ec1bd27bef30d8c934e"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca (AZN) Jumps to All-Time High on Trump Drug Tariff Delay",
    "summary": "We recently published 10 Stocks Stealing The Spotlight Today. AstraZeneca PLC (NASDAQ:AZN) is one of the top performers on Wednesday. AstraZeneca saw its share prices jump to a new all-time high on Wednesday, as investors cheered reports that President Donald Trump delayed the imposition of a 100-percent tariff on all pharmaceutical imports. A report by […]",
    "url": "https://finnhub.io/api/news?id=6724a13cb03b67895d66db9e82177e85ea7776f16f300ae1fe47c9fb63bd6ebc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759391335,
      "headline": "AstraZeneca (AZN) Jumps to All-Time High on Trump Drug Tariff Delay",
      "id": 136955466,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks Stealing The Spotlight Today. AstraZeneca PLC (NASDAQ:AZN) is one of the top performers on Wednesday. AstraZeneca saw its share prices jump to a new all-time high on Wednesday, as investors cheered reports that President Donald Trump delayed the imposition of a 100-percent tariff on all pharmaceutical imports. A report by […]",
      "url": "https://finnhub.io/api/news?id=6724a13cb03b67895d66db9e82177e85ea7776f16f300ae1fe47c9fb63bd6ebc"
    }
  },
  {
    "ts": null,
    "headline": "Heard on the Street Wednesday Recap: Hiring Freeze",
    "summary": "The government shutdown began. Government funding lapsed early Wednesday after the White House and lawmakers failed to reach a spending deal. Administration officials have said they plan to use the shutdown to cut jobs across agencies.",
    "url": "https://finnhub.io/api/news?id=f2eed7f76764f850aa418e1751f3db52e763f288afeb7343c515816f6531eafa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759389833,
      "headline": "Heard on the Street Wednesday Recap: Hiring Freeze",
      "id": 136955468,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The government shutdown began. Government funding lapsed early Wednesday after the White House and lawmakers failed to reach a spending deal. Administration officials have said they plan to use the shutdown to cut jobs across agencies.",
      "url": "https://finnhub.io/api/news?id=f2eed7f76764f850aa418e1751f3db52e763f288afeb7343c515816f6531eafa"
    }
  },
  {
    "ts": null,
    "headline": "BMO Capital Maintains Outperform on Pfizer (PFE) Amid New Obesity Partnership",
    "summary": "Pfizer Inc. (NYSE:PFE) ranks among the top picks for a retirement portfolio. BMO Capital reaffirmed its Outperform rating and $30 price target for Pfizer Inc. (NYSE:PFE) on September 23 in response to the company’s announcement of a new agreement in the obesity treatment market. Following disappointments with its lotiglipron and danuglipron programs, the pharmaceutical giant […]",
    "url": "https://finnhub.io/api/news?id=3e646b68a802980315f6a96e8f2e391befc6f981a110a60bdc94e414a295b0f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759388135,
      "headline": "BMO Capital Maintains Outperform on Pfizer (PFE) Amid New Obesity Partnership",
      "id": 136955469,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) ranks among the top picks for a retirement portfolio. BMO Capital reaffirmed its Outperform rating and $30 price target for Pfizer Inc. (NYSE:PFE) on September 23 in response to the company’s announcement of a new agreement in the obesity treatment market. Following disappointments with its lotiglipron and danuglipron programs, the pharmaceutical giant […]",
      "url": "https://finnhub.io/api/news?id=3e646b68a802980315f6a96e8f2e391befc6f981a110a60bdc94e414a295b0f7"
    }
  },
  {
    "ts": null,
    "headline": "GSK boss says US is ‘biggest priority’ as Trump pressures drugmakers",
    "summary": "The boss of Britain’s largest drugmaker has said the US is its “biggest priority” amid pressure from Donald Trump to slash prices for US citizens.",
    "url": "https://finnhub.io/api/news?id=ac2b25619ec496a9976f7602d8af704fc8e9a499b31712b86093f6b7fd4b56ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759383000,
      "headline": "GSK boss says US is ‘biggest priority’ as Trump pressures drugmakers",
      "id": 136955471,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The boss of Britain’s largest drugmaker has said the US is its “biggest priority” amid pressure from Donald Trump to slash prices for US citizens.",
      "url": "https://finnhub.io/api/news?id=ac2b25619ec496a9976f7602d8af704fc8e9a499b31712b86093f6b7fd4b56ae"
    }
  }
]